Keyword: Eli Lilly

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis, to the tune of $225 million.

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

With the failure of its lead program in pancreatic cancer, Halozyme is cutting drug development to focus solely on its drug delivery technology.

In a study of pet dogs with arthritis, a drug discovered at Eli Lilly reduced symptoms and signs of clinical pain. It could help people, too.

As Amgen rides the wave of hype and hope for its early-stage KRAS effort as well as other cancer assets, this is pushing out its work on neuroscience.

Eli Lilly diabetes chief Conterno will step down; MD Anderson's Hahn likely pick for FDA head; Amgen CFO Meline bows out.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.

As the industry’s digital transformation is fueled by tools such as AI and machine learning, certain R&D projects promise to have outsized impacts.

Last year, Eli Lilly spent $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin. Today, that drug flopped.

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.